Navigation Links
Pharmacopeia to Present at BIO CEO & Investor Conference 2008
Date:2/4/2008

PRINCETON, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the BIO CEO & Investor Conference 2008. The conference will be held February 11-13, 2008, at The Waldorf-Astoria Hotel in New York City.

Dr. Browne's presentation will take place at 2:00 p.m. EST on Tuesday, February 12th. The presentation will include an overview of the company's drug development pipeline, including an update on its internal clinical programs, PS433540 (DARA), which is progressing in Phase 2, and PS178990 (SARM), which is currently in Phase 1. A live webcast and 90-day archive of the presentation can be accessed at http://www.pharmacopeia.com.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corpora
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
2. Pharmacopeia Announces Third Quarter 2007 Financial Results
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
6. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
9. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...., Dec. 1 Vanda Pharmace... in The Lancet , one of the world,s leading medic...el circadian regulator, experimental compound tasi...et al(1) is entitled "Melatonin agonist tasimelteo...e shift: two randomised controlled multicentre tri...
(Date:12/1/2008)...y shows the Prox1 gene is a two-way switch that, i...o be reprogrammed so that they lose their identity... , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswi... Hospital have discovered that a certain different... that it requires the constant expression of a gen...
(Date:12/1/2008)... 1 GeoVax Labs, Inc.,(O...nology company developing,human vaccines for dise...) and,other infectious agents, announced today th...s will take place in twelve sites across North and...laboration with The National Institutes of,Health...
(Date:11/28/2008)... Nov. 28 Eli Lilly and C...tal New Drug Application (sNDA) from,the U.S. Foo...uloxetine HCl),for the management of chronic pain...first half of 2009, adding data from a recently co...pain of the knee. , The decision does not a...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 1Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 2Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 3New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 1New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 1Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 3UTSA UTHSCSA publish results on bio threat agent 7885 1UTSA UTHSCSA publish results on bio threat agent 7885 2
...Cancer and Other Human,Papillomavirus Related Dise...e Phase III Clinical Studies Which Included More T...e publishes the most comprehensive,and robust clin...YON, France, 10th May2007 – New clinical stu... of Gardasil® in the,prevention of cervical ca...
...007 - Antisense,Pharma, a German biopharmaceutical...ignant tumors, today announced, that data from the...a will be,presented at the 43rd Annual Meeting of ...which will be held in Chicago, Illinois,U.S.A, fr... dose-finding Phase,IIb-trial adult patients with ...
Other Medicine Technology:Gardasil Demonstrates Up to 100% Efficacy 2Gardasil Demonstrates Up to 100% Efficacy 3Gardasil Demonstrates Up to 100% Efficacy 4Gardasil Demonstrates Up to 100% Efficacy 5Gardasil Demonstrates Up to 100% Efficacy 6Gardasil Demonstrates Up to 100% Efficacy 72007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3
(Date:12/1/2008)...lain and colleagues, at Memorial Sloan-Kettering C...ach to modulate the expression of genes for therap... anticancer therapy in mice. , Small, noncoding ... repressors of gene expression. In the study, the ...on of genes in immune cells known as T cells at di...
(Date:12/1/2008)...inn. - Disturbing evidence of higher mortality and...al valve prolapse and severe leakage may be relate...severity in women, according to findings of a Mayo...of Internal Medicine . , Mitral valve prolapse a...and often requires cardiac surgery, preferably val...
(Date:12/1/2008)...ec. 1 ViroPharma Incorpo...company submitted a supplemental,Biologics Licens...inistration,(FDA) for Cinryze(TM) C1 Inhibitor (h...ary angioedema (HAE). , The sBLA is based o...votal,Phase 3 acute treatment study of Cinryze an...
(Date:12/1/2008)...Dec. 1 Media entrepreneur, televis...investor and philanthropist John,Bendheim will be... their,annual "Road To A Cure" Gala, December 2, ...Rick Powell, Chairman of the Board of Governors, c...ron Kaplan and Fran Solomon. The "Road To,A Cure...
Breaking Medicine News(10 mins):Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
...ke adults, children are likely to suffer hearing l...sic, power generators, drilling machines and firec...urvery says that 5 million children have noise-ind...f the loss is only in one ear, the child's overall...
...art disease, in any form is unquestionably one of ... planet. The scientists of the globe are working o...is better than cure. As a result of their hard wor...ify and stop the progression when the disease is y...
...abetes mellitus type I, is due to autoimmune destr...insulin. Result of this the body no longer produce...gar levels. Individuals with this type I Diabetes ...heart disease even at their teens. The team of res...
...DS in developing countries is a threeat to the glo...he United Nations General Assembly Special Session...e cost of anti retroviral therapy that would cater...s. Dr. Anne-Valerie Kaninda, medical advisor for D...
Other Medicine News:
Knot pusher/suture retriever
The RC Retractor comes with several blade sizes to allow for superficial or deep muscle retraction. The RC Retractor permits retraction in three different directions: medial, lateral and inferior.
Shoulder rasp
12" suture passer
Medicine Products: